লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
cerebrolysin 1076 mg/5 ml šķīdums injekcijām/koncentrāts infūziju šķīduma pagatavošanai
ever neuro pharma gmbh, austria - cerebrolizīns - Šķīdums injekcijām/koncentrāts infūziju šķīduma pagatavošanai - 1076 mg/5 ml
লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
cerebrolysin 2152 mg/10 ml šķīdums injekcijām/koncentrāts infūziju šķīduma pagatavošanai
ever neuro pharma gmbh, austria - cerebrolizīns - Šķīdums injekcijām/koncentrāts infūziju šķīduma pagatavošanai - 2152 mg/10 ml
লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
cerebrolysin 215,2 mg/ml šķīdums injekcijām/koncentrāts infūziju šķīduma pagatavošanai
ever neuro pharma gmbh, austria - cerebrolizīns - Šķīdums injekcijām/koncentrāts infūziju šķīduma pagatavošanai - 215,2 mg/ml
ইউরোপীয় ইউনিয়ন -
লাত্ভীয় -
EMA (European Medicines Agency)
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
ইউরোপীয় ইউনিয়ন -
লাত্ভীয় -
EMA (European Medicines Agency)
fanaptum
vanda pharmaceuticals ltd - iloperidons - Šizofrēnija - psihoterapija - Šizofrēnijas ārstēšanai.
লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
brinzolamide/timolol stada 10 mg/5 mg/ml acu pilieni, suspensija
stada arzneimittel ag, germany - brinzolamidum, timololum - acu pilieni, suspensija - 10 mg/5 mg/ml
লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
posaconazole stada 100 mg zarnās šķīstošās tabletes
stada arzneimittel ag, germany - posakonazols - zarnās šķīstošā tablete - 100 mg
লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
bortezomib stada 2,5 mg/ml šķīdums injekcijām
stada arzneimittel ag, germany - bortezomibs - Šķīdums injekcijām - 2,5 mg/ml
লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
sunitinib stada 12,5 mg cietās kapsulas
stada arzneimittel ag, germany - sunitinibs - kapsula, cietā - 12,5 mg
লাত্ভিয়া -
লাত্ভীয় -
Zāļu valsts aģentūra
sunitinib stada 25 mg cietās kapsulas
stada arzneimittel ag, germany - sunitinibs - kapsula, cietā - 25 mg